Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

INDV - Indivior PLC So'nggi Yangiliklar | Finranks

Home

INDV

I

Indivior PLC (INDV)

NMS – Real vaqt narxi. Valyuta: USD

28.97

-0.98 (-3.27%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

28.98

+0.01 (0.03%)

Bozordan keyin: Mar 27, 2026, 7:52 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV)

Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV)

The heavy selling pressure might have exhausted for Indivior Pharmaceuticals Inc. (INDV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid use disorder (MOUD) across U.S. correctional facilities.

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions.

Indivior Announces Proposed Convertible Senior Notes Offering

Indivior Announces Proposed Convertible Senior Notes Offering

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes.

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va.

Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript

Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript

Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript

Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates

Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates

Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.32 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid use disorder (MOUD) across U.S. correctional facilities.

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $400,000,000 aggregate principal amount of notes. Indivior also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $50,000,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on March 17, 2026, subject to customary closing conditions.

Indivior Announces Proposed Convertible Senior Notes Offering

Indivior Announces Proposed Convertible Senior Notes Offering

RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Indivior also expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $60,000,000 principal amount of notes.

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

Patients adherent to SUBLOCADE ® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUD Patients adherent to SUBLOCADE had the lowest inpatient, emergency department, and detoxification utilization across all treatment groups RICHMOND, Va.